Identifying direct risk factors in UK Biobank via simultaneous Bayesian-frequentist model-averaged hypothesis testing using Doublethink
Proceedings of the National Academy of Sciences · 2026
DOI: 10.1073/pnas.2514138122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Nicolas Arning und 2 weiteren Autor:innen. Beteiligte Einrichtung: Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, United Kingdom. Hauptthemen laut MEDLINE: COVID-19, Biological Specimen Banks. Die Arbeit nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust (WT), Royal Society (The Royal Society), National Institute for Health Research Health Protection Research Unit (NIHR HPRU).
Abstract (Originalsprache)
Big data approaches to discovering nongenetic risk factors have lagged behind genome-wide association studies that routinely uncover novel genetic risk factors for diverse diseases. Instead, epidemiology typically focuses on candidate risk factors. Since modern biobanks contain thousands of potential risk factors, candidate approaches may introduce bias, inadequately control for multiple testing, and overlook important signals. Doublethink, a model-averaged hypothesis testing approach, offers a solution that simultaneously controls the Bayesian false discovery rate (FDR) and frequentist familywise error rate (FWER) while accounting for uncertainty in variable selection. Here, we investigate direct risk factors for COVID-19 hospitalization from among 1,912 variables in 201,917 UK Biobank participants by implementing a Doublethink-based exposome-wide association study using Markov Chain Monte Carlo. Focusing on the 2020 outbreak, we find nine individual variables and seven groups of variables exposome-wide significant at 9% FDR and 0.05% FWER. We identify significant direct effects among relatively overlooked risk factors including aging, dementia, and prior infection, which we evaluate in relation to studies of other populations. We detect significant direct effects among some commonly reported risk factors like age, sex, and obesity, but not others like cardiovascular disease. The effects of hypertension, depression, and diabetes appeared to be mediated via general comorbidity. Doublethink produces interchangeable posterior odds and P -values for individual variables and arbitrary groups, facilitating flexible and powerful post hoc hypothesis testing. We discuss the potential for impact and limitations of joint Bayesian-frequentist hypothesis testing, including the benefits of an agnostic exposome-wide approach to discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, United Kingdom.
- Department for Continuing Education, University of Oxford, Oxford OX1 2JA, United Kingdom.
ORCID-Profile: Helen R Fryer, Daniel J Wilson
Förderung
- Wellcome Trust (WT)
- Royal Society (The Royal Society)
- National Institute for Health Research Health Protection Research Unit (NIHR HPRU)
- Robertson Foundation (The Robertson Foundation)
Zitieren
APA
Arning, N., Fryer, H. R., & Wilson, D. J. (2026). Identifying direct risk factors in UK Biobank via simultaneous Bayesian-frequentist model-averaged hypothesis testing using Doublethink. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2514138122
Vancouver
Arning N, Fryer HR, Wilson DJ. Identifying direct risk factors in UK Biobank via simultaneous Bayesian-frequentist model-averaged hypothesis testing using Doublethink. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2514138122
BibTeX
@article{Arning2026,
author = {Arning, Nicolas and Fryer, Helen R and Wilson, Daniel J},
title = {Identifying direct risk factors in UK Biobank via simultaneous Bayesian-frequentist model-averaged hypothesis testing using Doublethink},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
doi = {10.1073/pnas.2514138122}
}
EUVIMED